To include your compound in the COVID-19 Resource Center, submit it here.

Inhibiting endocytosis to enhance cetuximab, trastuzumab and Bavencio antitumor efficacy

DISEASE CATEGORY: Cancer

INDICATION: Breast cancer; colorectal cancer; skin cancer

Blocking endocytosis with DMN inhibitors could enhance the efficacy of cetuximab, trastuzumab and Bavencio avelumab

Read the full 238 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE